The polygenic risk score in the breast cancer treatment

Abstract

Breast cancer (BC) remains the most common cause of death in women worldwide, but advances in science have allowed earlier diagnosis and more comprehensive treatment. This review highlights the impact of extensive molecular genetic testing in assessing the risk of BC susceptibility, as well as possible responses to chemotherapy and radiotherapy. Studies in the literature show that several Single Nucleotide Polymorphisms (SNPs) of genes involved in molecular pathways may become predictors of the risk of developing BC. For example, SNPs in genes such as RAD51 and XRCC3, already known to be linked with high BC susceptibility, were also correlated with a different response to radiotherapy and related adverse effects. In addition, the SNP ESR1 PvuII (rs2234693), on the ESR1 gene, has been associated with a poor prognosis in advanced BC, but can be a good predictor of the therapeutic effect of hormonal treatment. Therefore, SNPs can be considered as possible new biomarkers for BC risk and prognosis. In this view, it is important to evaluate Polygenic Risk Score, an essential component for accurate BC risk prediction, which may potentially improve screening and prevention strategies. Bioinformatics tools are available to calculate polygenic risk by assessing the presence of SNPs and patients’ family and personal history. This represents an important step forward in the era of personalized medicine for BC.

Keywords

Breast cancer / polygenic risk score (PRS) / preventive medicine / oncology / risk prediction

References

[1] RobertsE,EvansDG.Polygenic risk scores and breast cancer risk prediction.Breast2023;67:71-7

[2] PurrahmanD,SakiN,Kurkowska-JastrzębskaI.Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer.Cytokine2022;151:155803

[3] TungN,MessersmithH.Selection of germline genetic testing panels in patients with cancer: ASCO guideline.J Clin Oncol2024;42:2599-615

[4] Di RadoS,CicirelliM.Detection of germline mutations in a cohort of 250 relatives of mutation carriers in multigene panel: impact of pathogenic variants in other genes beyond BRCA1/2.Cancers2023;15:5730 PMCID:PMC10741895

[5] AnaclerioF,Dell’EliceA.Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis.Front Genet2023;14:1060504 PMCID:PMC10104445

[6] MavaddatN,DennisJ.Polygenic risk scores for prediction of breast cancer and breast cancer subtypes.Am J Hum Genet2019;104:21-34

[7] BrittKL,PhillipsKA.Key steps for effective breast cancer prevention.Nat Rev Cancer2020;20:417-36

[8] EvansDGR,HarknessEF.Breast cancer risk stratification in women of screening age: incremental effects of adding mammographic density, polygenic risk, and a gene panel.Genet Med2022;24:1485-94

[9] SharmaGN,SanadyaJ,SharmaKK.Various types and management of breast cancer: an overview.J Adv Pharm Technol Res2010;1:109-26 PMCID:PMC3255438

[10] AkramM,DaniyalM.Awareness and current knowledge of breast cancer.Biol Res2017;50:33 PMCID:PMC5625777

[11] MichailidouK,DennisJ.Association analysis identifies 65 new breast cancer risk loci.Nature2017;551:92-4

[12] MilneRL,MichailidouK.Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.Nat Genet2017;49:1767-78

[13] LambertSA,InouyeM.Towards clinical utility of polygenic risk scores.Hum Mol Genet2019;28:R133-42

[14] VisscherPM,ZhangQ.et al. 10 years of GWAS discovery: biology, function, and translation.Am J Hum Genet2017;101:5-22 PMCID:PMC5501872

[15] AllmanR,HopperJL.SNPs and breast cancer risk prediction for African American and Hispanic women.Breast Cancer Res Treat2015;154:583-9 PMCID:PMC4661211

[16] DiteGS,BickerstaffeA.Breast cancer risk prediction using clinical models and 77 independent risk-associated snps for women aged under 50 years: Australian breast cancer family registry.Cancer Epidemiol Biomarkers Prev2016;25:359-65 PMCID:PMC4767544

[17] DiteGS,BickerstaffeA.Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model.Breast Cancer Res Treat2013;139:887-96 PMCID:PMC4059776

[18] LeeA,WilcoxAN.BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.Genet Med2019;21:1708-18 PMCID:PMC6687499

[19] ShiehY,MaL.Breast cancer risk prediction using a clinical risk model and polygenic risk score.Breast Cancer Res Treat2016;159:513-25 PMCID:PMC5033764

[20] LiH,MironA.Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab.Genet Med2017;19:30-5 PMCID:PMC5107177

[21] LaderianB,FojoT.Distribution of cancer genes in human chromosomes.Semin Oncol2020;47:409-13

[22] SudA,HoulstonR.Will polygenic risk scores for cancer ever be clinically useful?.NPJ Precis Oncol2021;5:40 PMCID:PMC8139954

[23] WangY,MaH.Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention.Med Rev2021;1:129-49 PMCID:PMC10471106

[24] TaylorLC,HutchinsonA,Usher-SmithJA.Acceptability of risk stratification within population-based cancer screening from the perspective of healthcare professionals: a mixed methods systematic review and recommendations to support implementation.PLoS One2023;18:e0279201 PMCID:PMC9956883

[25] HoWK,MavaddatN.European polygenic risk score for prediction of breast cancer shows similar performance in Asian women.Nat Commun2020;11:3833

[26] MavaddatN,MichailidouK.Prediction of breast cancer risk based on profiling with common genetic variants.J Natl Cancer Inst2015;107:djv036

[27] HoPJ,KhngAJ.Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.BMC Med2022;20:150

[28] LiJ,WenWX.Differential burden of rare and common variants on tumor characteristics, survival, and mode of detection in breast cancer.Cancer Res2018;78:6329-38

[29] SunYS,YangZN.Risk factors and preventions of breast cancer.Int J Biol Sci2017;13:1387-97 PMCID:PMC5715522

[30] JantzenR,deMalliard T,NoiselN.Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort.BMJ Open2021;11:e045078 PMCID:PMC8047995

[31] GailMH,ByarDP.Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.J Natl Cancer Inst1989;81:1879-86

[32] FarkasA,MerriamS.Breast cancer chemoprevention: a practical guide for the primary care provider.J Womens Health2020;29:46-56

[33] TyrerJ,CuzickJ.A breast cancer prediction model incorporating familial and personal risk factors.Stat Med2004;23:1111-30

[34] KarsonoR,KarsonoB,PratiwiY.ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.BMC Cancer2021;21:1348 PMCID:PMC8686387

[35] MarkiewiczA,SkokowskiJ.Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.PLoS One2013;8:e72219 PMCID:PMC3738574

[36] ReinertT,BarriosCH.Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer.Front Oncol2017;7:26 PMCID:PMC5350138

[37] YuJ.Relationship between polymorphisms in homologous recombination repair genes RAD51 G172T, XRCC2 & XRCC3 and risk of breast cancer: a meta-analysis.Front Oncol2023;13:1047336 PMCID:PMC9903134

[38] CastroE,GarciaA,González-SarmientoR.Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients.Clin Transl Oncol2014;16:158-65

[39] GoričarK,DolžanV.NBN, RAD51 and XRCC3 polymorphisms as potential predictive biomarkers of adjuvant radiotherapy toxicity in early HER2-positive breast cancer.Cancers2022;14:4365 PMCID:PMC9496855

[40] KleinRJ.Are polygenic risk scores ready for the cancer clinic? - a perspective.Transl Lung Cancer Res2022;11:910-9 PMCID:PMC9186162

[41] JuniorHLR,DatorreJG,ReisRM.Role of polygenic risk score in cancer precision medicine of non-European populations: a systematic review.Curr Oncol2022;29:5517-30 PMCID:PMC9406904

[42] EvansDG,ByersH.The importance of ethnicity: are breast cancer polygenic risk scores ready for women who are not of white European origin?.Int J Cancer2022;150:73-9 PMCID:PMC9290473

[43] LiuC,ChungWK.Generalizability of polygenic risk scores for breast cancer among women with European, African, and Latinx Ancestry.JAMA Netw Open2021;4:e2119084 PMCID:PMC8339934

[44] JiaG,GuoX.Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction.Nat Genet2024;56:819-26 PMCID:PMC11284829

[45] CoignetMV,RobertsMR.Genetic variations, reproductive aging, and breast cancer risk in African American and European American women: the women’s circle of health study.PLoS One2017;12:e0187205 PMCID:PMC5658184

[46] DixonP,TaylorJC,MartinRM.Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review.Genet Med2022;24:1604-17 PMCID:PMC7614235

[47] DannhauserFC,TungJSL.The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review.J Commun Genet2024;15:217-34 PMCID:PMC11217210

[48] LopesCardozo JMN,BojesenSE.Associations of a breast cancer polygenic risk score with tumor characteristics and survival.J Clin Oncol2023;41:1849-63

[49] YiangouK,DennisJ.Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction. medRxiv 2024

[50] PadrikP,TõnissonN.Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice.Breast Cancer2023;17:11782234231205700 PMCID:PMC10571698